Syndax Pharmaceuticals Inc - Common Stock, par value $0.0001 per share (SNDX)

Historical Holders from Q1 2016 to Q4 2025

Type / Class
Equity / Common Stock, par value $0.0001 per share
Symbol
SNDX on Nasdaq
Shares outstanding
86,559,040
Price per share
$21.01
All holders as of 30 Sep 2025
Q3 2025
Total 13F shares as of 30 Sep 2025
101,141,226
Total reported value
$1,556,073,766
% of total 13F portfolios
0.01%
Share change
-672,117
Value change
+$19,277,989
Avg buy value change
+0%
Avg sell value change
-0%
Number of holders
225
Price from insider filings
$16.41
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Significant Owners of Syndax Pharmaceuticals Inc - Common Stock, par value $0.0001 per share (SNDX) based on Schedule 13D/G filings

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
Kynam Capital Management, LP 10% $95,083,200 8,520,000 Kynam Capital Management, LP 31 Dec 2024
BlackRock, Inc. 7.8% $75,263,587 6,744,049 BlackRock, Inc. 31 Mar 2025
GOLDMAN SACHS GROUP INC 6.5% +26% $85,960,152 +$16,495,849 5,581,828 +24% THE GOLDMAN SACHS GROUP, INC. 30 Jun 2025
Point72 Asset Management, L.P. 5% +77% $66,650,461 +$31,109,971 4,327,952 +88% Point72 Asset Management, L.P. 15 Aug 2025
MORGAN STANLEY 2.4% -65% $22,766,545 -$37,075,261 2,040,013 -62% Morgan Stanley 31 Mar 2025
WELLINGTON MANAGEMENT GROUP LLP 0% $398,200 35,681 Wellington Management Group LLP 28 Feb 2025
As of 30 Sep 2025, Syndax Pharmaceuticals Inc - Common Stock, par value $0.0001 per share (SNDX) has 225 institutional shareholders filing 13F forms. They hold 101,141,226 shares. .

Top 25 institutional shareholders own 84% of the company.

Filer Ownership Nb Shares Share Change % Portfolio % Holdings Value
BlackRock, Inc. 10% 8,625,244 -18% 0% $132,699,393
Kynam Capital Management, LP 9.8% 8,520,000 0% 9.8% $131,080,200
GOLDMAN SACHS GROUP INC 6.3% 5,486,434 -5.4% 0.01% $84,408,787
VANGUARD GROUP INC 5.9% 5,138,617 +2.1% 0% $79,057,621
Point72 Asset Management, L.P. 4.9% 4,255,047 +100% 0.14% $65,463,921
STATE STREET CORP 4.5% 3,853,549 +12% 0% $59,286,852
BANK OF AMERICA CORP /DE/ 4.3% 3,697,753 -3.7% 0% $56,889,929
Eversept Partners, LP 4% 3,467,314 -15% 4.1% $53,344,626
ADAGE CAPITAL PARTNERS GP, L.L.C. 3.8% 3,311,963 +131% 0.08% $50,954,551
KINGDON CAPITAL MANAGEMENT, L.L.C. 2.9% 2,500,000 +19% 6% $38,462,500
FRANKLIN RESOURCES INC 2.8% 2,390,561 +1.3% 0.01% $36,778,786
GEODE CAPITAL MANAGEMENT, LLC 2.4% 2,091,331 +2% 0% $32,179,868
Soleus Capital Management, L.P. 2.3% 2,012,110 +84% 1.7% $30,956,312
Assenagon Asset Management S.A. 2.1% 1,784,139 -13% 0.04% $27,448,979
UBS Group AG 1.9% 1,674,513 +17% 0.01% $25,762,382
Qube Research & Technologies Ltd 1.9% 1,644,844 -1.3% 0.04% $25,305,925
Catalio Capital Management, LP 1.9% 1,614,717 -23% 4.6% $24,842,421
Woodline Partners LP 1.8% 1,550,520 -18% 0.11% $23,854,750
Nuveen, LLC 1.7% 1,475,798 +455% 0.01% $22,705,153
MPM BIOIMPACT LLC 1.6% 1,375,674 3.5% $21,164,744
STEMPOINT CAPITAL LP 1.6% 1,366,205 -42% 4.2% $21,019,064
Aisling Capital Management LP 1.5% 1,316,806 0% 4.4% $20,265,644
BNP PARIBAS ASSET MANAGEMENT Holding S.A. 1.4% 1,236,077 -14% 0.05% $19,017,000
MORGAN STANLEY 1.4% 1,199,296 +41% 0% $18,451,176
D. E. Shaw & Co., Inc. 1.2% 1,077,585 +67% 0.01% $16,578,645

Institutional Holders of Syndax Pharmaceuticals Inc - Common Stock, par value $0.0001 per share (SNDX) across Reporting Periods

Period Reported Shares, Excl. Options Value, Excl. Options Value Change Price (% of par) Investors
2025 Q4 226,524 $4,745,679 -$34,525,105 2,101% 9
2025 Q3 101,141,226 $1,556,073,766 +$19,277,989 1,538.5% 225
2025 Q2 101,743,087 $952,765,629 -$3,412,810 936.5% 214
2025 Q1 100,841,762 $1,238,937,511 +$32,280,106 1,228.5% 215
2024 Q4 98,036,362 $1,295,984,146 +$87,202,806 1,322% 214
2024 Q3 88,967,889 $1,713,503,848 +$22,771,373 1,925% 210
2024 Q2 87,289,213 $1,792,028,805 -$71,145,019 2,053% 194
2024 Q1 90,291,619 $2,148,803,697 +$42,533,190 2,380% 189
2023 Q4 174,087 $3,762,020 -$348,017 2,161% 2
2023 Q3 70,980,290 $1,030,927,112 -$1,573,210 1,452% 173
2023 Q2 70,453,851 $1,474,579,645 -$31,621,147 2,093% 163
2023 Q1 72,963,785 $1,540,531,010 +$25,297,246 2,112% 160
2022 Q4 71,342,730 $1,815,639,083 +$262,569,530 2,545% 154
2022 Q3 59,545,066 $1,430,878,131 +$97,795,173 2,403% 130
2022 Q2 54,462,607 $1,047,862,225 +$14,504,684 1,923.99% 111
2022 Q1 54,372,350 $944,902,792 +$25,956,418 1,737.99% 133
2021 Q4 52,262,237 $1,143,309,026 +$54,334,941 2,188.98% 128
2021 Q3 48,910,008 $934,793,416 -$21,190,727 1,911% 121
2021 Q2 50,034,258 $859,008,071 +$11,927,670 1,716.99% 113
2021 Q1 48,482,747 $1,083,971,550 +$47,141,608 2,236% 130
2020 Q4 46,437,679 $1,032,905,433 +$270,034,091 2,224% 139
2020 Q3 34,234,522 $505,295,990 +$23,533,417 1,476% 97
2020 Q2 32,291,643 $478,555,331 +$172,833,456 1,482% 94
2020 Q1 20,701,860 $227,094,767 +$45,274,271 1,097.02% 78
2019 Q4 14,504,770 $127,350,479 -$3,741,854 878% 68
2019 Q3 14,964,592 $111,782,063 -$712,960 747.04% 68
2019 Q2 14,886,958 $138,591,343 +$4,609,716 930.99% 66
2019 Q1 16,954,829 $89,014,600 +$8,084,917 525% 64
2018 Q4 15,417,244 $68,602,620 -$2,847,096 444.99% 71
2018 Q3 15,338,118 $123,909,644 +$3,408,975 807.98% 71
2018 Q2 15,085,227 $105,895,984 -$23,252,865 702% 81
2018 Q1 17,172,873 $244,373,660 +$5,208,312 1,423.03% 72
2017 Q4 16,022,417 $140,348,672 +$22,954,619 876% 75
2017 Q3 15,034,508 $175,968,675 -$8,277,258 1,170% 67
2017 Q2 15,705,504 $219,397,678 +$56,766,070 1,396.92% 63
2017 Q1 11,652,824 $159,872,123 +$30,201,376 1,371.94% 62
2016 Q4 11,117,355 $79,710,466 -$4,869,455 716.96% 53
2016 Q3 11,598,197 $175,828,071 +$19,916,533 1,516% 44
2016 Q2 10,263,556 $101,043,565 +$10,817,004 984.96% 46
2016 Q1 9,440,571 $125,586,000 +$125,586,093 1,331.99% 26